KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 96 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,258,938 | +22.6% | 234,573 | +14.6% | 1.83% | +55.3% |
| Q2 2023 | $1,842,480 | +197.8% | 204,720 | +160.1% | 1.18% | +179.8% |
| Q1 2023 | $618,739 | +16.3% | 78,720 | 0.0% | 0.42% | +14.7% |
| Q4 2022 | $532,147 | -53.4% | 78,720 | 0.0% | 0.37% | -49.7% |
| Q3 2022 | $1,142,000 | +47.4% | 78,720 | 0.0% | 0.73% | +37.0% |
| Q2 2022 | $775,000 | -33.2% | 78,720 | 0.0% | 0.53% | -3.3% |
| Q1 2022 | $1,160,000 | +11.4% | 78,720 | 0.0% | 0.55% | +78.6% |
| Q4 2021 | $1,041,000 | -24.2% | 78,720 | 0.0% | 0.31% | -30.0% |
| Q3 2021 | $1,374,000 | -27.1% | 78,720 | 0.0% | 0.44% | -24.9% |
| Q2 2021 | $1,886,000 | – | 78,720 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |